Keeping Pace with the Evolving Treatment Management of MS to Improve Patient Outcomes:
Latest Considerations Around the Impact of MS Treatments on Immune Response

Release Date: November 15, 2022
Expiration Date: May 31, 2024
Estimated Time to Complete Activity: 0.75 hour
Compatible with all modern browsers and mobile devices

Expert Faculty Author:


	Léorah Freeman, MD, PhD Neurologist Multiple Sclerosis and Neuroimmunology Mulva Clinic for the Neurosciences Click here for biography

	Jacqueline F. Rosenthal, MD Neurologist, MS Institute Andrew C. Carlos Multiple Sclerosis Institute Click here for biography

	Julian Gamboa MS Community Representative

Target Audience
The primary target audience for this initiative consists of neurologists, nurse practitioners & nurses, pharmacists, physician assistants, and other health care professionals involved in treatment and management of patients with MS.

Statement of Need/Program Overview
More than a dozen disease-modifying therapies (DMTs) are available for the treatment of MS with several additional novel therapies in late-stage development. Early diagnosis and aggressive treatment are essential to minimize the MS disease burden and limit use of limited health care resources. The continually evolving MS treatment landscape, the impact of COVID-19, and addressing health disparities in the MS community accentuates the need for increased disease and therapeutic knowledge amongst MS advanced practice providers in order to optimize clinical outcomes, reduce treatment variability, and increase patient engagement in their own care.

Educational Objectives
After completing this activity, the participant should be better able to:

Describe the short and long-term implications of DMTs on the immune system and vaccine response in people with MS
Assess strategies to increase patient awareness of the need for the full spectrum of indicated vaccinations

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Multiple Sclerosis Association of America (MSAA), and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-457-H01-P
Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Léorah Freeman, MD, PhD	Consultant/Advisory Board – Genentech, Inc, Novartis, EMD Serono, Bristol Myers Squibb, TG Therapeutics Contracted Research - Genentech, Inc, EMD Serono
Jacqueline F. Rosenthal, MD	Consulting Fees (e.g., advisory boards): EMD Serono, TG Therapeutics, Horizon Therapeutics
Julian Gamboa	No financial interest/relationships relating to the topic of this activity.

The PIM, MSAA and Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print. For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.